Capricor Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $25.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Capricor Therapeutics’ progress with their product, Deramiocel. The company has recently received clarity from the FDA regarding the regulatory pathway for Deramiocel following a Type A meeting. This meeting confirmed alignment on key aspects of the HOPE-3 study, with the topline results anticipated by the fourth quarter of 2025. The inclusion of left ventricular ejection fraction (LVEF) as a key secondary endpoint in the BLA resubmission suggests potential regulatory flexibility, which could lead to dual labeling opportunities for Deramiocel based on both cardiac and skeletal muscle function benefits.
Furthermore, Capricor is well-funded into 2026, supporting ongoing regulatory activities and the potential commercial launch of Deramiocel. The HOPE-3 study, a comprehensive Phase 3 trial, has been completed, and the data is expected to be submitted as an amendment to the current BLA. The company’s valuation considers the potential commercial launch of Deramiocel for Duchenne muscular dystrophy in 2027, with a revenue risk adjustment and a discount rate applied to account for clinical trial risks and development stages. These factors collectively underpin McCarthy’s optimistic outlook and Buy rating for Capricor Therapeutics.
In another report released today, Oppenheimer also maintained a Buy rating on the stock with a $22.00 price target.
CAPR’s price has also changed dramatically for the past six months – from $13.480 to $6.520, which is a -51.63% drop .